Analysis of Chlamydia Re-testing Rates Massachusetts 2008-2009 Family Planning Update.

Slides:



Advertisements
Similar presentations
Re-testing for Chlamydia trachomatis Infection in Massachusetts Family Planning Clinics Marie E. Caggiano, William G. Dumas, Thomas E. Bertrand, Katherine.
Advertisements

Repeat Infections among Adolescents and Young Adults: Findings From Philadelphia STD Clinics Nicole Liddon, PhD 1 Michael Eberhart, BS 2 Jami Leichliter,
Assessment of Chlamydia Rescreening Practices Kelly Opdyke, MPH Region II IPP Advisory Committee Mtg May 16-17, 2007 Cicatelli Associates Inc.
How to Measure the Effectiveness of the IPP (and all the CT Screening being done)? **Reduce Infertility** Ultimate Goal Reduce PID Reduce Chlamydia Prevalence.
Partnering with hospital emergency departments Caroline Moseley, M.Ed. Mark Schulz, Ph.D. Manjunath Mahadevappa, MBBS, MPH.
STD Screening in HIV Clinics: Value and Implications Thomas Farley, MD MPH Tulane University Deborah Cohen, MD MPH RAND Corporation.
Impact of a Targeted Provider Intervention to Improve Chlamydia Screening Practices in a Large California Family Planning Program Joan M. Chow 1, MPH,
Prevention and Management of Sexually Transmitted Diseases in Persons Living with HIV/AIDS Partner Management.
The Relationship Between Repeat Infections and Behavioral Risk Factors and Clinician Counseling: Findings from a Philadelphia STD Clinic M. Eberhart 1,
Revision of Region II IPP Screening Criteria May 16, 2007 Region II IPP Advisory Committee Meeting Cicatelli Associates Inc. New York City.
Repeat Chlamydial Infections in Region III Family Planning Clinics: Implications for Screening Programs Pamela G. Nathanson, Family Planning Council, Inc.
Effect of Physician Asthma Education on Health Care Utilization of Children at Different Income Levels Randall Brown, Noreen Clark, Niko Kaciroti, Molly.
2014 PATIENT HISTORY How would you diagnose and screen Miranda? How would you treat Miranda? Are there any additional steps you would take? Antimicrobial.
Unit 4: Monitoring Data Quality For HIV Case Surveillance Systems #6-0-1.
Copyright © 2014 Wolters Kluwer Health | Lippincott Williams & Wilkins Chapter 1 Overview of Nursing Process, Clinical Reasoning, and Nursing Practice.
Expedited Partner Therapy in Wisconsin STD Control Section Wisconsin Division of Public Health June 2010.
Midwest AIDS Training & Education Center Health Care Education & Training, Inc. HIV/AIDS Case-Finding In Family Planning Clinics.
Evaluation of Gonorrhea Screening in Family Planning Settings: California 2000 CK Kent, M Brammeier, G Bolan, N Casas, M Funabiku, P Blackburn Region IX.
Appropriate CT/GC Screening & Factors to Consider Becky McCoy MSN, RN, CEN STD Nurse Consultant.
Surveillance to measure impact of ART Theresa Diaz, MD MPH CDC Global AIDS Program.
Tracking from Birth: Massachusetts Universal Newborn Hearing Screening Program MCHB/CDC Annual Meeting on Successful Statewide EHDI Programs Presenter:
The Variations and Deviations in the Use of Tympanostomy Tubes for Children with Otitis Media Salomeh Keyhani MD MPH Lawrence C. Kleinman MD MPH Michael.
North Dakota Department of Health STD Program Update Region 8 GC Control Meeting November 2009.
Re-Screening of CT Positive Clients in Region X IPP, Goldenkranz S., 1 Fine D. 1 1 Center for Health Training 2010 CDC STD Prevention Meeting,
Unit 5: Specialised Techniques: STI Prevalence Assessment and Combined STI/HIV Behavioural Surveillance Surveys #4-5-1.
SSuN Cycle 2 Conference call #5 Population-based gonorrhea surveillance Lori Newman & Kristen Mahle November 13, 2008.
Trends in Clinic Visits and Diagnosed C. trachomatis and N. gonorrhoeae Infections Following the Introduction of a Co-Pay in an STD Clinic C. Rietmeijer.
Region I IPP Clinic Staff and Provider Assessment Kim Watson, Jennifer Kawatu.
Components of HIV/AIDS Case Surveillance: Case Report Forms and Sources.
Gonorrhea Increases In Washington State: Gonorrhea Increases In Washington State: Analyses for intervention planning May 2011 Mark R. Stenger Infectious.
The Impact of Introducing “Express Visits” for Asymptomatic Persons Seeking STD Services in a Busy Urban STD Clinic System, Borrelli J 1, Paneth-Pollak.
Increasing the Efficiency of STI Clinics by Tailoring Services Based on a Risk Triage System Julie A. Subiadur, BSN, CCRC BC Brandy Mitchell, RN Dean McEwen.
US Virgin Islands IPP: Use of Limited Resources Taetia Phillips-Dorsett, MS Territorial Director, USVI DOH STD/HIV/TB Program Region II IPP Advisory Meeting.
1 TITLE X FAMILY PLANNING/HIV INTEGRATION PROJECT Opt Out Process Michael Brannon M.S. HIV/STD Prevention Program Manager (713)
GC Outbreak in Philadelphia Greta Anschuetz, MPH Philadelphia Department of Public Health
SSuN: MSM prevalence monitoring and HIV Testing in STD Clinics Kristen Mahle & Lori Newman SSuN Call #3 Oct 30, 2008.
Expedited Partner Therapy The Denver Experience Cornelis A. Rietmeijer, MD, PhD Denver Public Health Department National Coalition of STD Directors Phoenix,
Collecting Site Positivity Data in Region I Andee Krasner, MPH Region I IPP Advisory Board Meeting.
Pilot Study: Re-screening Adolescent and Young Adult Women for Chlamydia Infection Alison Muse NYSDOH Bureau of STD Control Region II IPP meeting November.
Utilization of Cross-matching Databases to Obtain Chlamydia Re-screening and Re-infection Rates for Family Planning/Infertility Prevention Project Clinics:
Region II IPP Data & Infrastructure Performance Measures Kelly Opdyke, MPH Region II IPP Advisory Committee Mtg May 16-17, 2007 Cicatelli Associates Inc.
Comprehensive Field Record. Introduction to the Training ● The slides will first show a picture of the section of the template that will be discussed.
IPP Measures of Effectiveness Utilization of Data to Evaluate and Inform Project Activities December 12, 2007 Kelly Morrison Opdyke, MPH Region II Infertility.
The California Gonorrhea Surveillance System California Department of Public Health STD Control Branch Contact info: Rain Mocello, MPH
Infrastructure Update Jennifer Kawatu Kim Watson Andee Krasner
Targeting Chlamydia Screening Resources Region II IPP Advisory Meeting May 31, 2006 Kelly Opdyke, MPH Cicatelli Associates Inc.
BASELINE ASSESSMENT OF CHLAMYDIA REINFECTION IN REGION VIII FAMILY PLANNING CLINICS FOR Hamby, Y, JSI Research & Training Institute Donovan,
Predicting Pregnancy Risk among Women Attending an STD Clinic Judith Shlay MD, MSPH Denver Public Health September 21, 2008 CityMatCH Conference.
Focus Area 25 Sexually Transmitted Diseases Progress Review July 21, 2004.
Region I IPP Data Presentation Advisory Board Meeting June 2008 Wells, ME.
Region II Infertility Prevention Project Advisory Committee May 16-17, 2007 New York, New York Steven J. Shapiro Infertility Prevention Project Coordinator.
IPP Infrastructure Measures of Effectiveness: Preliminary Data and Next Steps Kelly Morrison Opdyke, MPH Region II Infertility Prevention Project Cicatelli.
CONCLUSIONS New Jersey’s Emergency Department HIV testing sites report higher seroprevalence than non-ED testing sites. Since University Hospital began.
Spartanburg Family Medicine Residency
It's not what you know, but who you know: Risk factors for re-infection in the Philadelphia High School STD Screening Program Jennifer Beck, MPH APHA.
Cost of Screening Outside of IPP Chlamydia Screening Guidelines
National STD Conference 2008
Martin Goldberg1, Daniel R. Newman2, TA Peterman2,
Steven J. Shapiro Infertility Prevention Project Coordinator
Accelerated Partner Therapy (APT) index patient and sex partner flow diagram, clinics A and B. (1) Number of clinic attenders diagnosed with chlamydia,
Poster WP41; Contact: David A. Katz,
Family Planning & STDP Brainstorming
Can Self-collected Vaginal Swabs Facilitate Testing for Repeat Chlamydia trachomatis Infections among STD Clinic Clients Good morning everyone! I am going.
M Javanbakht, S Guerry, LV Smith, P Kerndt
Region I IPP Data Update Region I IPP Advisory Board Meeting
2008 National STD Prevention Conference Chicago, Illinois
May 9, 2006 National STD Prevention Conference
Region II IPP Performance Measure IPP CS1 and IPP CS2 Project Area Trend Report IPP CS1: Timely treatment of women with chlamydia at IPP Family Planning.
Region I IPP Data Update Region I IPP Advisory Board Meeting
Treatment Verification Rates for Chlamydia and Gonorrhea
Presentation transcript:

Analysis of Chlamydia Re-testing Rates Massachusetts Family Planning Update

Background “Repeat infections confer an elevated risk for PID and other complications when compared with the initial infection. Therefore, recently infected women are a major priority for repeat testing for C. trachomatis. Clinicians and health-care agencies should consider advising all women with chlamydial infection to be retested approximately 3 months after treatment. Providers also are strongly encouraged to retest all women treated for chlamydial infection whenever they next seek medical care within the following 3–12 months, regardless of whether the patient believes that her sex partners were treated.” (From CDC’s 2006 STD Treatment Guidelines )

Background Purpose of this analysis: –Assess usefulness of interventions to increase retesting rates –Feedback to clinics –Compare to other regions in the United States

Conclusions from MA Baseline Analysis ( data) Among women tested for Chlamydia at Massachusetts family planning clinics, approximately 29% were re-tested within 3-12 months of initial diagnosis –25% of women re-tested for chlamydia had recurrent infection Age < 18 years was associated with greater rates of re-testing

Intervention In 2006, MDPH began a monthly “report-back” system to notify clinics of positives and facilitate call backs for re-testing. Bill Dumas faxed lists once a month to the family planning clinics. The lists had names of patients who tested positive for Chlamydia 3 months ago and were due for a rescreen. Was this intervention effective at increasing Chlamydia re-testing rates at the family planning clinics?

Methods for the Update Records reviewed in 3 lab databases at MA State Lab for females with positive Chlamydia tests at IPP clinics between 1/1/2008 and 12/31/2008. I looked for follow-up tests through 12/31/2009. Variables used: Name and DOB (for match), specimen #, facility name and type, race/ethnicity, date of original specimen collection, date and result of follow-up test. SAS 9.1 used for analysis Fisher’s exact test to compare proportions

Proportion of Women at Family Planning Clinics Re-tested for Chlamydia 3-12 Months ( Days) after Initial Positive Diagnosis N= N= Results in Family Planning Clinics P=0.0495

Proportion of Positives in Women in FP Clinics Re-tested for Chlamydia 3-12 Months ( Days) after Initial Positive Diagnosis N= N=107 P=0.0483

Within each age group, what percent of women in FP clinics got re-tested? Women < 18 years Women > 18 years N=75N=225 N=104N=297 P= P=0.0260

Percent of Women in FP Clinics Re-tested for Chlamydia by Race/Ethnicity

Conclusions Rescreening rates significantly increased from 29% ( ) to 36% ( ). Of the women who re-tested in : –15% of women re-tested for chlamydia had recurrent infection –Age < 18 years still associated with greater rates of re-testing.

Strengths of this analysis Easily available electronic data I’ll be able to break down results by individual clinic and share results with them. SAS code can be modified for alternate re- testing timeframes, to compare with analyses in other regions of the U.S.

Limitations Re-testing rates may be higher than this data shows, if clinics sent 2 nd test to different lab. No chart review was done at clinics for this analysis. Only State Lab databases were used. Findings based on retrospective record review with only a limited number of factors available for analysis. Re-testing analysis cannot currently be done at the regional level using IPP database, because we don’t use client IDs. This analysis used names and dates of birth to identify patients.

Next Steps What do you think is the next intervention we should use to increase re-testing rates? It will be interesting to combine these results of this analysis with results from other New England states, and compare Region I to other regions. Contact me if you want more info on methods, so you can conduct an analysis in your state: Laura Smock, Data Manager for the Massachusetts IPP, MA Dept of Public Health, (617)